Targeted RNA Sequencing Market Regional Analysis, Demand Analysis and Competitive Outlook 2025-2032

MARKET INSIGHTS

The global targeted RNA sequencing market size was valued at USD 2.05 billion in 2024. The market is projected to grow from USD 2.55 billion in 2025 to USD 9.10 billion by 2031, exhibiting a remarkable CAGR of 24.4% during the forecast period.

Targeted RNA sequencing (RNA-Seq) is a sophisticated and highly accurate methodology used for selecting and sequencing specific transcripts of interest. Unlike broader whole-transcriptome approaches, this technique offers both quantitative gene expression data and qualitative information, such as the detection of splice variants and gene fusions. It is typically accomplished through two primary approaches: enrichment-based sequencing, which captures specific RNA regions using probes, and amplicon-based sequencing, which uses PCR to amplify targets of interest.

This significant market expansion is primarily fueled by the escalating demand for precision medicine and the critical need for high-resolution analysis in oncology and rare disease research. While the technology provides unparalleled depth of coverage for specific genes, making it cost-effective for focused studies, its adoption is further accelerated by continuous advancements in next-generation sequencing (NGS) platforms. The competitive landscape is characterized by a moderate level of competition, with key players like Thermo Fisher, Illumina, and Roche Holdings collectively commanding a significant portion of the market share. North America currently leads in market consumption, a trend driven by substantial research funding and advanced healthcare infrastructure.

MARKET DRIVERS

Growing Demand in Oncology and Rare Disease Research

The targeted RNA sequencing market is experiencing significant growth, primarily fueled by its critical role in precision medicine. There is a substantial increase in demand from oncology research, where the technology is essential for discovering and validating novel biomarkers, and from rare disease diagnostics, where it enables the detection of low-frequency transcripts and fusion genes with high sensitivity.

Declining Cost and Improved Accessibility of Sequencing Platforms

The overall cost of next-generation sequencing (NGS) has decreased considerably, making targeted RNA-seq a more accessible and cost-effective option for a broader range of research and clinical laboratories. This increased affordability is accelerating the adoption of this technology, which offers a more focused and efficient alternative to whole transcriptome sequencing.

The global market for targeted RNA sequencing is projected to grow at a compound annual growth rate exceeding 15% over the next five years, driven by its utility in pharmaceutical R&D.

Furthermore, advancements in automation and streamlined bioinformatics pipelines are reducing the technical barriers and hands-on time required, making the workflow more amenable to high-throughput clinical and research environments.

MARKET CHALLENGES

High Initial Capital Investment and Operational Complexity

Despite declining sequencing costs, the initial capital investment for high-throughput NGS instruments and the associated infrastructure remains a significant entry barrier for many small and mid-sized laboratories. Additionally, the workflow involves complex steps from library preparation to data analysis, requiring specialized expertise.

Other Challenges

Sample Quality and Standardization
The quality and integrity of RNA samples are paramount for reliable targeted RNA-seq results. Variations in sample collection, handling, and storage can introduce biases and affect data reproducibility, creating a challenge for standardizing protocols across different laboratories.

Data Analysis and Interpretation Bottlenecks
The generation of large, complex datasets necessitates robust computational resources and bioinformatician expertise for accurate interpretation. The lack of standardized analytical pipelines can lead to inconsistencies, posing a challenge for clinical adoption and comparative studies.

MARKET RESTRAINTS

Stringent Regulatory Frameworks for Clinical Applications

The transition of targeted RNA sequencing from a research tool to a clinically validated diagnostic application is hindered by stringent regulatory requirements. Obtaining approval from bodies like the FDA or EMA for RNA-based assays involves rigorous validation of accuracy, reproducibility, and clinical utility, which is a lengthy and costly process.

Competition from Alternative Profiling Technologies

The market faces competition from established and emerging technologies such as qPCR, microarrays, and digital PCR for certain applications. For rapid, high-throughput screening of a limited number of targets, these alternative methods can be more cost-effective and faster, restraining the growth of targeted RNA-seq in some segments.

MARKET OPPORTUNITIES

Expansion into Liquid Biopsy and Non-Invasive Diagnostics

A major opportunity lies in applying targeted RNA sequencing to liquid biopsies for cancer and other diseases. The ability to profile cell-free RNA from blood samples offers a powerful, non-invasive method for disease monitoring, treatment response assessment, and early detection, opening up vast clinical markets.

Development of Integrated Multi-Omics Solutions

There is a growing trend towards integrated multi-omics analyses. Companies that can offer solutions combining targeted RNA-seq with DNA sequencing or proteomic data from the same sample are well-positioned to capture significant market share by providing a more comprehensive view of biological systems for both research and clinical diagnostics.

Key Industry Players

A Market Dominated by a Handful of Major Life Science Giants

The global Targeted RNA Sequencing market is characterized by concentrated competition, with a small group of established life science and diagnostic corporations holding significant market share. Thermo Fisher Scientific, Illumina, and Roche Holdings are the unequivocal leaders, providing comprehensive platforms that include sequencers, reagents, and associated services. BGI and Eurofins Scientific also rank among the top players, contributing to a scenario where the top five companies collectively command approximately 52% of the global market. This leadership is largely driven by their robust R&D capabilities, extensive product portfolios, and strong global distribution and service networks, particularly dominant in the North American and European markets which account for nearly 60% of global consumption.

Beyond the market leaders, the landscape includes a diverse range of specialized service providers and genomics companies that compete in specific niches or geographic regions. These players, such as LabCorp and Berry Genomics, often focus on offering high-quality, customized sequencing services to research institutes, biotech companies, and diagnostic labs. Other significant competitors include companies like Macrogen and GENEWIZ (part of Azenta Life Sciences), which have built strong reputations for reliable sequencing services. The market also features agile, specialized firms that cater to emerging applications or offer competitive pricing, contributing to the overall diversity and dynamism of the industry, though the market as a whole is not considered intensely competitive.

• Thermo Fisher Scientific

• Illumina, Inc.

• Roche Holding AG

• BGI Group

• Eurofins Scientific

• Laboratory Corporation of America Holdings (LabCorp)

• Berry Genomics

• Macrogen, Inc.

• GENEWIZ (Azenta Life Sciences)

• Q2 Solutions

• Novogene Co., Ltd.

• Psomagen, Inc.

• Genomics England

• DNA Link, Inc.

• Source BioScience

The global Targeted RNA Sequencing market is experiencing significant growth, with its value projected to increase from 2046 million in 2024 to 9101 million by 2031, representing a compound annual growth rate (CAGR) of 24.4%. This robust expansion is largely fueled by the critical role of targeted RNA-Seq in precision medicine, particularly in oncology for gene expression analysis and the detection of novel gene fusions. The technology's ability to provide highly accurate quantitative and qualitative data from a focused set of genes makes it indispensable for biomarker discovery and therapeutic development, driving adoption across research and clinical settings.

Methodological Segmentation: Enrichment vs. Amplicon Sequencing

The market is segmented by methodology into Enrichment Sequencing and Amplicon Sequencing. Enrichment-based approaches are gaining significant traction as they offer the distinct advantage of detecting both known and novel gene fusion partners across various sample types. This capability is crucial for comprehensive genomic profiling in cancer research. Amplicon sequencing remains a strong contender for applications requiring high sensitivity for specific, known targets. The choice between these methods is a key trend, driven by the specific research or diagnostic question, cost considerations, and desired throughput.

Geographically, North America is the largest market, holding a consumption share of nearly 32%, followed by Europe with a 28% share. This dominance is attributed to advanced healthcare infrastructure, high R&D expenditure, and early adoption of genomic technologies. The competitive landscape is led by a few major players, including Thermo Fisher, Illumina, Roche Holdings, BGI, and Eurofins, which collectively hold approximately 52% of the market share. While competition is not yet intense, the market's high growth potential is attracting increased attention, with key companies focusing on service enhancements and strategic developments to capture a larger market segment, particularly in emerging applications within biotechnology companies and diagnostic laboratories.

Europe
Europe represents a highly significant and technologically advanced market for targeted RNA sequencing, characterized by a strong collaborative research landscape. The region benefits from multi-national initiatives that promote standardization and data sharing, such as those funded by the European Commission. Countries like Germany, the UK, and France are particular hotspots, with robust national health systems that are increasingly integrating molecular diagnostics. While regulatory pathways through bodies like the EMA are rigorous, they provide a clear framework for clinical adoption. The presence of several leading diagnostic companies and a growing focus on personalized medicine, especially in oncology, drives consistent market growth. However, market fragmentation due to varying national reimbursement policies presents a nuanced challenge compared to the more unified North American market.

Asia-Pacific
The Asia-Pacific region is the fastest-growing market for targeted RNA sequencing, fueled by expanding healthcare infrastructure, rising research funding, and increasing awareness of precision medicine. Countries such as China, Japan, and South Korea are making substantial government-led investments in genomics, leading to a rapid expansion of sequencing capabilities. A large patient population provides a substantial base for clinical research and the application of diagnostic tests. Local companies are increasingly developing and manufacturing their own targeted panels, reducing reliance on imports and making the technology more accessible. While the market is burgeoning, growth is uneven, with advanced economies leading adoption while emerging markets gradually build the necessary technical expertise and regulatory frameworks.

South America
The targeted RNA sequencing market in South America is in a developing phase, with growth primarily concentrated in larger economies like Brazil and Argentina. Market expansion is driven by increasing research collaborations, a growing prevalence of chronic diseases requiring molecular diagnosis, and gradual improvements in healthcare infrastructure. Adoption is largely centered in major academic and research hospitals in urban centers, with application focuses including infectious disease research and specific cancer studies. Challenges include limited funding for advanced genomic tools, regulatory hurdles, and a reliance on imported technologies and reagents, which can increase costs and slow down implementation compared to more established markets.

Middle East & Africa
The Middle East & Africa region presents an emerging but fragmented market for targeted RNA sequencing. Growth is predominantly seen in wealthy Gulf Cooperation Council (GCC) countries, such as the United Arab Emirates and Saudi Arabia, which are investing heavily in healthcare modernization and genomic medicine initiatives as part of economic diversification plans. These nations are establishing specialized genomic centers. In contrast, adoption across the broader African continent is minimal, hindered by significant infrastructure limitations, funding constraints, and pressing basic healthcare needs. The market potential is long-term, reliant on international partnerships and gradual infrastructure development to build capacity for advanced genomic applications.

Report Scope

This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.

Key Coverage Areas:

• Market Overview

  • Global and regional market size (historical & forecast)

  • Growth trends and value/volume projections

• Segmentation Analysis